Dudediligence.

Kura Oncology, Inc

KURANASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$14.1MMar ’25$15.3MJun ’25$20.8MSep ’25$17.3MDec ’25$18.3MMar ’26$20.9MJun ’26
Net income, by quarter
−$54.4MSep ’24−$19.2MDec ’24−$57.4MMar ’25−$66.1MJun ’25−$74.1MSep ’25−$81.0MDec ’25−$73.3MMar ’26−$68.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on file$0.00$53.9M$67.5M
Operating incomenone on file−$139.9M−$165.8M−$193.2M−$303.6M
Net income−$130.5M−$135.8M−$152.6M−$174.0M−$278.7M
Operating cash flow−$104.6M−$110.1M−$124.8M$134.3M−$64.1M
Free cash flow−$105.7M−$110.7M−$125.0M$133.8M−$70.7M
Cash$90.7M$51.8M$37.3M$224.5M$149.1M
Debtnone on file$9.2M$9.3M$9.5M$9.7M
Shares outstanding66.6M68.3M74.3M78.2M87.9M